Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Moderna Inc., consolidated balance sheet: assets (quarterly data)

US$ in millions

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash and cash equivalents 2,932 3,801 3,441 3,205 3,027 2,873 5,048 6,848 5,550 5,603 5,442 2,624 1,506 1,762 392 236 174 152 503
Investments 4,641 4,658 5,482 6,697 5,321 5,024 5,067 3,879 3,356 2,387 2,293 1,984 1,771 955 826 867 885 919 606
Accounts receivable 1,866 232 1,113 1,385 2,695 2,691 3,173 3,175 3,142 2,020 3,210 1,391 191 33 7 5 8 5 7
Inventory 487 715 732 949 2,077 1,921 1,942 1,441 965 643 494 47
Prepaid expenses and other current assets 873 1,193 1,354 1,195 1,177 1,054 1,120 728 412 316 264 253 110 46 25 20 28 23 25
Current assets 10,799 10,599 12,122 13,431 14,297 13,563 16,350 16,071 13,425 10,969 11,703 6,298 3,577 2,797 1,250 1,129 1,094 1,097 1,141
Investments, non-current 5,273 6,105 7,442 8,318 8,655 10,162 9,171 6,843 6,442 4,207 468 639 692 355 502 160 280 365 438
Property, plant and equipment, net 1,952 2,280 2,018 2,018 2,019 1,324 1,341 1,241 845 794 372 297 277 230 202 201 204 209 213
Right-of-use assets, operating leases 765 130 117 121 113 122 132 142 115 104 89 90 92 92 101 86
Deferred tax assets 1,480 1,262 982 920 785 521 326 81 66 50
Other non-current assets 661 1,290 1,164 988 52 87 94 46 15 13 12 13 13 12 13 13 13 14 14
Non-current assets 8,651 11,285 12,003 12,427 11,759 12,480 11,259 8,598 7,498 5,184 991 1,039 1,074 689 818 461 496 588 665
Total assets 19,450 21,884 24,125 25,858 26,056 26,043 27,609 24,669 20,923 16,153 12,694 7,337 4,651 3,486 2,068 1,589 1,591 1,685 1,806

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Moderna Inc. current assets decreased from Q1 2023 to Q2 2023 but then slightly increased from Q2 2023 to Q3 2023.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Moderna Inc. property, plant and equipment, net increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.
Non-current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Moderna Inc. non-current assets decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Moderna Inc. total assets decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Moderna Inc. cash and cash equivalents increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.
Investments Amount of investment in marketable security, classified as current. Moderna Inc. investments decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Accounts receivable Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Moderna Inc. accounts receivable decreased from Q1 2023 to Q2 2023 but then increased from Q2 2023 to Q3 2023 exceeding Q1 2023 level.
Inventory Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Moderna Inc. inventory decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.